Related Experiment Video
Updated: Aug 15, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy
1Department of Lymphoma/Myeloma, Univeristy of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Therapy with rituximab is the most important advance in the treatment of lymphomas since the development of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Rituximab has single-agent activity in all types of B-cell lymphomas, including indolent and aggressive disease. For large-cell lymphomas, rituximab plus chemotherapy represents a significant advance over chemotherapy alone without significant added toxicity. Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)